LifeStance Health Group, Inc. (NASDAQ:LFST) Stock Has Average Price Target of $13.12

LifeStance Health Group, Inc. (NASDAQ:LFST) has received an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $13.38.

A number of equities research analysts recently issued reports on the stock. Canaccord Genuity Group increased their target price on shares of LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. BTIG Research boosted their price target on shares of LifeStance Health Group from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday. Barclays upped their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Thursday, September 10th. Weiss Ratings raised shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Finally, Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q3 adjusted earnings were $0.06 per share, ahead of analyst estimates, while revenue reached $455.9 million versus a roughly $431.6 million consensus and grew 25.3% year over year. Zacks Q3 results
• Positive Sentiment: LifeStance raised its full-year outlook, adding to the favorable earnings and revenue surprise. Q3 results and outlook
• Positive Sentiment: BTIG Research raised its price target from $18 to $20 and maintained a Buy rating, signaling increased analyst confidence. BTIG Research ratings
• Neutral Sentiment: Despite the upbeat results and analyst action, LFST traded lower during the session; the provided coverage does not establish a specific cause for the move.

LifeStance Health Group Trading Down 5.4%

Shares of LFST stock opened at $13.45 on Friday. The stock has a market cap of $5.14 billion, a price-to-earnings ratio of 103.46 and a beta of 1.35. The firm has a fifty day moving average of $12.59 and a 200-day moving average of $9.46. LifeStance Health Group has a 52-week low of $5.10 and a 52-week high of $15.66. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The firm had revenue of $455.86 million during the quarter, compared to analyst estimates of $431.59 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The company’s revenue for the quarter was up 25.3% compared to the same quarter last year. On average, equities research analysts forecast that LifeStance Health Group will post 0.16 earnings per share for the current fiscal year.

Insider Transactions at LifeStance Health Group

In related news, COO Lisa Miller sold 47,912 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the sale, the chief operating officer directly owned 281,289 shares in the company, valued at $3,051,985.65. This represents a 14.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the sale, the insider directly owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. This represents a 12.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,777,580 shares of company stock valued at $146,433,781 in the last three months. 3.50% of the stock is owned by corporate insiders.

Institutional Trading of LifeStance Health Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. IFP Advisors Inc boosted its stake in shares of LifeStance Health Group by 316.5% during the 2nd quarter. IFP Advisors Inc now owns 3,694 shares of the company’s stock worth $40,000 after buying an additional 2,807 shares during the last quarter. KBC Group NV bought a new stake in LifeStance Health Group during the first quarter worth about $29,000. Signaturefd LLC raised its holdings in LifeStance Health Group by 35.6% during the third quarter. Signaturefd LLC now owns 5,357 shares of the company’s stock worth $64,000 after acquiring an additional 1,405 shares in the last quarter. USA Financial Formulas acquired a new position in LifeStance Health Group during the third quarter valued at approximately $71,000. Finally, EverSource Wealth Advisors LLC boosted its position in LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after purchasing an additional 5,404 shares during the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.